UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 199

Sortiert nach

First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC

British journal of cancer, 2014-04, Vol.110 (8), p.1917-1922

2014

Volltextzugriff (PDF)

The impact of prior platinum therapy on survival in patients with metastatic urothelial cancer receiving vinflunine

British journal of cancer, 2013-11, Vol.109 (10), p.2548-2553

2013

Volltextzugriff (PDF)

Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)

Annals of oncology, 2018-02, Vol.29 (2), p.361-369

2018

Volltextzugriff (PDF)

Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)

Annals of oncology, 2019-11, Vol.30 (11), p.1841-1841

2019

Volltextzugriff (PDF)

Activity of cabozantinib (cabo) after PD-1/PD-L1 immune checkpoint blockade (ICB) in metastatic clear cell renal cell carcinoma (mccRCC)

Annals of oncology, 2018-10, Vol.29, p.viii311-viii311

2018

Volltextzugriff (PDF)

Pharmacokinetic (PK) analysis of concurrent administration of enzalutamide (enza) and crizotinib (crizo) in patients with metastatic castration resistant prostate cancer (CRPC)

Annals of oncology, 2018-10, Vol.29, p.viii298-viii298

2018

Volltextzugriff (PDF)

Use of bone health agents (BHAs) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) after abiraterone (Abi): An interim review of REASSURE

Annals of oncology, 2018-10, Vol.29, p.viii288-viii288

2018

Volltextzugriff (PDF)

Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCC-A Possible Path Forward

Kidney cancer, 2017-07, Vol.1 (1), p.31-40

2017

Volltextzugriff (PDF)

Evaluation of disease‐free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial‐level meta‐analysis

Cancer, 2018-03, Vol.124 (5), p.925-933

2018

Volltextzugriff (PDF)

Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle‐invasive bladder cancer

Cancer, 2019-09, Vol.125 (18), p.3155-3163

2019

Volltextzugriff (PDF)

826PUse of bone health agents (BHAs) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) after abiraterone (Abi): An interim review of REASSURE

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

852PPharmacokinetic (PK) analysis of concurrent administration of enzalutamide (enza) and crizotinib (crizo) in patients with metastatic castration resistant prostate cancer (CRPC)

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

879PActivity of cabozantinib (cabo) after PD-1/PD-L1 immune checkpoint blockade (ICB) in metastatic clear cell renal cell carcinoma (mccRCC)

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

Effect of fulvestrant on PSA doubling time in patients with castration-resistant prostate cancer (CRPC)

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.e15112-e15112

2010

Volltextzugriff (PDF)

Treatment of refractory metastatic renal cell carcinoma (RCC) with bevacizumab and RAD001

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.TPS236-TPS236

2010

Volltextzugriff (PDF)

Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)

European urology, 2017-02, Vol.71 (2), p.281-289

2017

Volltextzugriff (PDF)

The economic and clinical costs of chronic kidney disease following radical and partial nephrectomy in the management of small renal masses

Journal of clinical oncology, 2011-03, Vol.29 (7_suppl), p.353-353

2011

Volltextzugriff (PDF)

Association of body mass index (BMI) with progression-free survival (PFS) in patients with advanced renal cell cancer (RCC) treated with targeted therapies

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.e15103-e15103

2011

Volltextzugriff (PDF)

Prospective cardiotoxicity screening during tyrosine kinase inhibitor therapy for renal cell carcinoma: An institutional experience

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.e16003-e16003

2009

Volltextzugriff (PDF)

ERCC1 and RRM1 expression patterns in synchronous primary and metastatic urothelial cancer lesions

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.e15035-e15035

2011

Volltextzugriff (PDF)

Bevacizumab-associated erythrocytosis in metastatic renal cell carcinoma (mRCC)

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.16096-16096

2008

Volltextzugriff (PDF)

Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)

Annals of oncology, 2019-11, Vol.30 (11), p.1841

2019

Volltextzugriff (PDF)

A phase II trial of calcitrol and naproxen in recurrent prostate cancer

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.16103-16103

2008

Volltextzugriff (PDF)

External validation of the International Metastatic Renal Cell Carcinoma (mRCC) Database Consortium prognostic model and comparison to four other models in the era of targeted therapy

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.4560-4560

2011

Volltextzugriff (PDF)

Correlation of RRM1 expression in muscle invasive locally advanced urothelial cancer with age

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.e16021-e16021

2009

Volltextzugriff (PDF)

1 – 25 von 199

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(181)
Mit Volltextzugriff
(193)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(121)
Life Sciences & Biomedicine
(77)
Humans
(46)
Physical Sciences
(36)
Male
(25)
Female
(23)
Oncology
(23)
Urology & Nephrology
(22)
Animals
(20)
Biological And Medical Sciences
(20)
Physics
(18)
Astronomy & Astrophysics
(17)
Middle Aged
(17)
Aged
(15)
Biochemistry & Molecular Biology
(14)
Molecular Sequence Data
(12)
Science & Technology - Other Topics
(12)
Urology
(12)
Adult
(11)
Tumors
(11)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC

The impact of prior platinum therapy on survival in patients with metastatic urothelial cancer receiving vinflunine

Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)

Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)

Activity of cabozantinib (cabo) after PD-1/PD-L1 immune checkpoint blockade (ICB) in metastatic clear cell renal cell carcinoma (mccRCC)

Pharmacokinetic (PK) analysis of concurrent administration of enzalutamide (enza) and crizotinib (crizo) in patients with metastatic castration resistant prostate cancer (CRPC)

Use of bone health agents (BHAs) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) after abiraterone (Abi): An interim review of REASSURE

Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCC-A Possible Path Forward

Evaluation of disease‐free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial‐level meta‐analysis

Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle‐invasive bladder cancer

826PUse of bone health agents (BHAs) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) after abiraterone (Abi): An interim review of REASSURE

852PPharmacokinetic (PK) analysis of concurrent administration of enzalutamide (enza) and crizotinib (crizo) in patients with metastatic castration resistant prostate cancer (CRPC)

879PActivity of cabozantinib (cabo) after PD-1/PD-L1 immune checkpoint blockade (ICB) in metastatic clear cell renal cell carcinoma (mccRCC)

Effect of fulvestrant on PSA doubling time in patients with castration-resistant prostate cancer (CRPC)

Treatment of refractory metastatic renal cell carcinoma (RCC) with bevacizumab and RAD001

Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)

The economic and clinical costs of chronic kidney disease following radical and partial nephrectomy in the management of small renal masses

Association of body mass index (BMI) with progression-free survival (PFS) in patients with advanced renal cell cancer (RCC) treated with targeted therapies

Prospective cardiotoxicity screening during tyrosine kinase inhibitor therapy for renal cell carcinoma: An institutional experience

ERCC1 and RRM1 expression patterns in synchronous primary and metastatic urothelial cancer lesions

Bevacizumab-associated erythrocytosis in metastatic renal cell carcinoma (mRCC)

Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)

A phase II trial of calcitrol and naproxen in recurrent prostate cancer

External validation of the International Metastatic Renal Cell Carcinoma (mRCC) Database Consortium prognostic model and comparison to four other models in the era of targeted therapy

Correlation of RRM1 expression in muscle invasive locally advanced urothelial cancer with age

Suchergebnisse filtern